Riskpilot← Back to searchSign inGet full accessNeuroLing Oy
OYDissolvedY-tunnus 3256398-3Teknobulevardi 35Other human health activities n.e.c. · NACE 8699Est. 2021— employees
Revenue 2025
EUR 561K
+43% vs 2024
EBITDA margin
8.3%
-94% vs 2024
Equity ratio
67.8%
Financial strength
Net profit 2025
EUR 37K
+216% vs 2024
| Revenue | EUR 561K | +43% |
| EBITDA | EUR 46K | -94% |
| Net profit | EUR 37K | +216% |
| Total assets | EUR 97K | +12% |
| Equity | EUR 66K | +111% |
| Employees | — | — |
Legal name
NeuroLing Oy
Y-tunnus number
3256398-3
Legal form
Osakeyhtiö
NACE code
8699 · Other human health activities n.e.c.
Founded
22. joulukuuta 2021
Share capital
EUR 0
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala on puheterapia-alan palvelut ja kaikki muu laillinen liiketoiminta.
Address
Teknobulevardi 35
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 337 | 392 | 561 |
| Staff expenses | — | 7 | 11 | −32 |
| EBITDA | −14 | 632 | 768 | 46 |
| Depreciation & amort. | — | — | — | — |
| EBIT | −14 | 42 | 15 | 46 |
| Net financials | −1 | — | — | — |
| Profit before tax | −16 | 40 | 15 | 46 |
| Tax | −0 | 5 | 3 | −9 |
| Net profit | −16 | 35 | 12 | 37 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 12 | 48 | 87 | 97 |
| Equity | −16 | 19 | 31 | 66 |
| Long-term debt | 27 | 5 | 0 | — |
| Short-term debt | 1 | 24 | 56 | 31 |
| Total debt | 28 | 29 | 56 | 31 |
EBITDA margin
8.3%
This company
15.8%
Market median
-47% vs market
20222025
Equity ratio
67.8%
This company
38.2%
Market median
+77% vs market
20222025
Return on equity
56.4%
This company
18.4%
Market median
+207% vs market
20222025
Net profit margin
6.6%
This company
8.1%
Market median
-19% vs market
20222025
Asset turnover
5.78×
This company
1.12×
Market median
+416% vs market
20222025
Debt / equity
0.47×
This company
0.62×
Market median
+24% vs market
20222025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2021-12-01 – 2022-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
JA Deputy Member | Deputy Member | 2022 |
HO Deputy Member | Deputy Member | 2022 |
MJ Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairperson | 2022 | |
| Former (1) | ||
| Board of Directors | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NeuroLing Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jani Antero Kivikari | Deputy Member | 0 companies |
| Henrik Olli Johannes Asplund | Deputy Member | 0 companies |
| Meri Jenny Emilia Asplund | Chief Executive Officer | 0 companies |
| Henna Anneli Kivikari | Chairperson | 0 companies |
| Saara Sisko Elisa Peteri | Board of Directors | 0 companies |